3 October 2024 F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic.
Cambridge, USA-based biotech incubator Flagship Pioneering today unveiled Abiologics, a company reimagining biologics with the creation of a new class of supranatural and programmable medicines, called Synteins. 23 July 2024
Swiss pharma giant Roche and US biotech Regeneron are on the cusp of transforming the vascular endothelial growth factor A (VEGF-A) therapy market with their revolutionary treatments, Vabysmo (faricimab), and Eylea HD (aflibercept). 23 July 2024
UK-based Touchlight, a CDMO advancing enzymatic DNA production to enable the genetic medicine revolution, has announced a license agreement with London-based pharma major GSK (LSE: GSK). 23 July 2024
HIV specialist ViiV Healthcare, which is majority owned by UK pharma major GSK, today announced 48-week findings from PASO DOBLE (GeSIDA 11720 study). 23 July 2024
Latigo Biotherapeutics, a privately-held US biotech focused on developing non-opioid pain medicines, has appointed Nima Farzan as chief executive. 23 July 2024
Beijing, China-based Gan & Lee Pharmaceuticals announced that its independently developed long-acting GLP-1 receptor agonist (GLP-1 RA), GZR18 injection, has achieved positive results in a clinical trial for adults with obesity/overweight in China. 23 July 2024
In San Francisco, RAPT Therapeutics (Nasdaq: RAPT) has announced a substantial workforce reduction as part of its cash conservation strategy. 23 July 2024
SIGA Technologies (Nasdaq: SIGA) has announced a significant procurement option exercised by the US health authorities, an order for $113 million worth of oral Tpoxx (tecovirimat). 23 July 2024
Yesterday, the US Food and Drug Administration (FDA) issued a draft guidance, Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products. 23 July 2024
California-based liver and viral disease specialist Aligos Therapeutics (Nasdaq: ALGS) has announced a clinical trial collaboration with Amoytop Biotech. 23 July 2024
Agilent Technologies has signed a definitive agreement to acquire Biovectra, a leading specialized contract development and manufacturing organization (CDMO), for $925 million. 23 July 2024
Chugai today announced it will transfer to Maruishi Pharmaceuticals the business in Japan concerning the physiological intestinal function improving and hyperammonemia drug Monilac 22 July 2024
The Organization of Pharmaceutical Producers of India (OPPI) has urged the government to exempt patented and orphan drugs from price control. 22 July 2024
The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) submitted by South Korea’s Samsung Bioepis for Epysqli (eculizumab-aagh) as a biosimilar to Soliris (eculizumab). 22 July 2024
A new collaboration in the area of stem cell therapies is to get underway in Japan, as Tokyo-based drugmaker Astellas Pharma (TSE: 4503) pairs up with Osaka University. 22 July 2024
STADA Arzneimittel and Iceland-based Alvotech have launched Uzpruvo, the first approved biosimilar to Stelara (ustekinumab) in Europe, across a majority of European countries. 22 July 2024
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
The European Medicines Agency’s pharmacovigilance committee, PRAC, has started a review of medicines containing finasteride and dutasteride following concerns regarding suicidal ideation (suicidal thoughts) and behaviors. 4 October 2024
Opioid Use Disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs and prolonged self-administration of opioid drugs. 4 October 2024
Proposals from the National Health Service (NHS) England have been set out for a phased launch of Eli Lilly’s obesity injection Mounjaro/Zepbound (tirzepatide) at the start of a consultation. 4 October 2024
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. 3 October 2024
Israel’s Teva Pharmaceutical Industries and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a global licensing deal for the development of an anti PD-1 oncology biosimilar candidate. 3 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Abivax ABVX) today announced the results of an interim efficacy and safety analysis of an open-label maintenance (OLM) study that enrolled patients with ulcerative colitis (UC). 3 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.